Systematic Review of Combinative Effects of Anluo Huaxian Pills with Nucleotide Analogues on Liver Fibrosis Due to Chronic Hepatitis B

WANG Chen-xiao; LUO Wei-sheng; GUO Xiao; KANG Yi

doi:10.13422/j.cnki.syfjx.2015070203

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Combinative Effects of Anluo Huaxian Pills with Nucleotide Analogues on Liver Fibrosis Due to Chronic Hepatitis B

更新时间：2024-09-23

- Systematic Review of Combinative Effects of Anluo Huaxian Pills with Nucleotide Analogues on Liver Fibrosis Due to Chronic Hepatitis B
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 7, Pages: 203-209(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015070203
  CLC： R512.62;R575.2
- Published：2015
- 稿件说明：
移动端阅览
WANG Chen-xiao, LUO Wei-sheng, GUO Xiao, et al. Systematic Review of Combinative Effects of Anluo Huaxian Pills with Nucleotide Analogues on Liver Fibrosis Due to Chronic Hepatitis B[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(7): 203-209.
DOI：

WANG Chen-xiao, LUO Wei-sheng, GUO Xiao, et al. Systematic Review of Combinative Effects of Anluo Huaxian Pills with Nucleotide Analogues on Liver Fibrosis Due to Chronic Hepatitis B[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(7): 203-209. DOI： 10.13422/j.cnki.syfjx.2015070203.

摘要

目的: 通过收集安络化纤丸联合核苷(酸)类抗病毒药物治疗慢性乙型肝炎肝纤维化的临床随机对照试验和半随机对照试验进行系统评价

评估安络化纤丸联合核苷(酸)类抗病毒药物治疗慢性乙型肝炎肝纤维化疗效及安全性。方法: 根据相关检索式计算机检索中国知网、万方数据系统、维普生物医药数据库

Medline

EMbase

CBM 数据库

收集关于安络化纤丸联合核苷(酸)类抗病毒药物治疗慢性乙型肝炎肝纤维化的随机对照试验

按照国际Cochrane 协作网的系统评价方法进行评价

由两名评价员分别独立对符合纳入标准的试验进行质量评价和资料提取

然后交叉核对。结果: 共有7个临床试验纳入本研究

7项研究方法学质量均较差

且存在较大的偏倚风险。安络化纤丸联合核苷(酸)类抗病毒药物组对比单用抗病毒药物组在改善肝纤维化和肝功能方面有一定的优势。联合用药可以降低肝纤维化血清学标志物透明质酸(hyaluronic acid

HA)

层粘连蛋白(laminin

LN)

Ⅳ型胶原(type IV collagen

Ⅳ-c)水平

在改善肝功能方面

能降低丙氨酸转氨酶(alanine aminotransferase

ALT)

天门冬氨酸转氨酶(aspartarte aminotransferase

AST)水平。但是对降低Ⅲ型前胶原肽(procollagen type III

P-Ⅲ-P)水平、减轻患者脾脏肿大程度和门脉高压、提高血清白蛋白(albumin

Alb)含量、降低总胆红素(total bilirubin

TBIL)含量的影响差异没有统计学意义。结论: 但由于文献质量均较低

故仍需要多中心

大样本的高质量的随机对照临床研究

以期做出更为严谨的系统评价。

Abstract

Objective: The aim of this study was to systematically evaluate the efficacy of Anluo Huaxian pills combined with nucleotide analogues in treating liver fibrosis resulting from chronic hepatitis B. Method: Medline

Embase

CNKI

CBM

VIP

and Wanfang database were searched to collect Randomized controlled trials (RCT) about cases of treating liver fibrosis resulting from chronic hepatitis B using Anluo Huaxian pills combined with nucleotide analogues. Result: Seven clinical trials were included. The Cochrane Collaboration's method was used for data analysis. Compared with using nucleotide analogues alone

the combination of nucleotide analogues and Anluo Huaxian Wan can significantly improve the degree of liver fibrosis and liver function indices. Combination medication might decrease serum levels of hyaluronic acid(HA) and laminin(LH)

type IV collagen(IV-c)

and in the respect of improving the liver function

combination medication might decrease serum levels of alanine aminotransferase(ALT)

aspartarte aminotransferase(AST). Conclusion: But the differences in the decrease of serum levels of PC-Ⅲ

improvement of splenomegaly and portal hypertension

increase of serum levels of albumin(Alb) was not statistically significant.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism and Combination Therapy of Berberine in Treatment of Nonalcoholic Fatty liver Disease：A Review

Clinical Efficacy of Gandou Fumu Granules in Intervention of Liver Fibrosis in WD Patients with Phlegm and Blood Stasis Syndrome and Effect on Cuproptosis-related Indicators

Gandouling Regulates PI3K/Akt/mTOR Autophagy Signaling Pathway via LncRNA H19 for Treatment of Wilson Disease Liver Fibrosis

Efficacy and Safety of Lianhua Qingwen Preparation in Treatment of Community-acquired Pneumonia：A Systematic Review and Meta-analysis

Mechanism of Shugan Huazheng Prescription Against Liver Fibrosis Based on HIF-1α/VEGF/TGF-β₁ Pathway

Related Author

WANG Xiaojie

ZHANG Heng

LIU Sutong

ZHANG Lihui

ZHAO Wenxia

WANG Fei

JIANG Zhenzhen

CHEN Yimin

Related Institution

Henan General Hospital

The First Clinical Medical College of Henan University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

Graduate School of Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰